Kwamitin Kimiyya na Turai kan Kare Kayayyakin Mabukaci (SCCS) kwanan nan ya fitar da ra'ayoyin farko game da amincin ethylhexyl methoxycinnamate (EHMC) da ake amfani da su a cikin kayan kwalliya. EHMC matatar UV ce da aka saba amfani da ita, ana amfani da ita sosai a cikin samfuran hasken rana.
Babban ƙarshe shine kamar haka: 1 SCCS ba zai iya tantance ko amfani da EHMC a matsakaicin matsakaicin 10% a cikin kayan shafawa yana da lafiya. Dalili kuwa shi ne, bayanan da ake da su ba su isa ba don kawar da cututtukan da ke tattare da shi. Akwai shaidun da za su ba da shawarar cewa EHMC yana da aikin rushewa na endocrine, gami da babban aikin estrogenic da rauni na aikin anti androgenic a cikin duka a cikin vivo da gwaje-gwajen in vitro Saboda dalilan da ke sama, SCCS kuma ba ta iya samar da matsakaicin matsakaicin matsakaicin EHMC don amfani a ciki. kayan shafawa. SCCS ya nuna cewa wannan kima bai ƙunshi tasirin aminci na EHMC akan muhalli ba.
Bayanin bango: EHMC a halin yanzu an yarda a yi amfani da shi azaman kariya ta rana a cikin ƙa'idodin kayan kwalliyar EU, tare da matsakaicin matsakaicin 10%. EHMC galibi yana ɗaukar UVB kuma ba zai iya karewa daga UVA ba. EHMC yana da tarihin amfani na shekaru da yawa, tun da a baya an yi gwajin aminci a cikin 1991, 1993, da 2001. A cikin 2019, EHMC an haɗa shi cikin jerin ƙimar fifikon EU na 28 m masu rushewar endocrine.
A halin yanzu ana neman ra'ayi na farko a bainar jama'a don yin tsokaci, tare da wa'adin ranar 17 ga Janairu, 2025. SCCS za ta tantance bisa la'akari da bayar da ra'ayi na ƙarshe a nan gaba.
Wannan ra'ayi na iya shafar ƙa'idodin amfani na EHMC a cikin kayan kwalliyar EU. Biwei ya ba da shawarar cewa ya kamata kamfanoni masu dacewa da masu siye su sa ido sosai kan ci gaban da ke gaba.
Lokacin aikawa: Nuwamba-20-2024
